These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35437256)

  • 41. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
    World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
    Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
    World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.
    Barlow LJ; Seager CM; Benson MC; McKiernan JM
    Urol Oncol; 2010; 28(1):108-11. PubMed ID: 20123359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
    Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
    Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.
    Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA
    Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radical cystectomy compared to intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer - is there a long-term survival difference? A Swedish nationwide analysis.
    Wang EY; Larsson U; Gårdmark T; Malmström PU
    Scand J Urol; 2021 Feb; 55(1):46-52. PubMed ID: 33305681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Smoke load prognostic impact on bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer.
    Andrade DL; Moretti TBC; Neto WA; Benedetti J; Reis LO
    Int Urol Nephrol; 2020 Aug; 52(8):1471-1476. PubMed ID: 32157620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.